Brief: Silexion Therapeutics Announces Significant New Data From Phase 2 Trial Of Loder In Non-Resectable Pancreatic Cancer

Silexion Therapeutics

24/09/2024 12:17

Sept 24 (Reuters) - Silexion Therapeutics Corp  SLXN.O :
    * SILEXION THERAPEUTICS CORP: ANNOUNCES SIGNIFICANT NEW DATA
FROM
PHASE 2 TRIAL OF LODER™ IN NON-RESECTABLE PANCREATIC CANCER
    * SILEXION : PHASE 2 TRIAL OF LODER SHOWS A 56% OBJECTIVE
RESPONSE
RATE (ORR) & 67% RESECTABILITY IMPROVEMENT IN NON-RESECTABLE
PANCREATIC CANCER

Source text for Eikon:  ID:n0001178913-24-003126 
Further company coverage:  SLXN.O 

 ((Reuters.Briefs@thomsonreuters.com))